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Background. Malignant mesothelioma (MM) is an aggressive tumor of the serosal membranes, mostly the pleura. It is related
to asbestos exposure and has a poor prognosis. MM has a long latency period, and incidence is predicted to remain stable or
increase until 2020. Currently, no biomarkers for a specific targeted therapy are available. Previously, we observed that expression
of aquaporin 1 (AQP1) was an indicator of prognosis in two independent cohorts. Here we determine whether AQP1 inhibition
has therapeutic potential in the treatment of MM.Methods. Functional studies were performed with H226 cells and primary MM
cells harvested from pleural effusions. AQP1 expression and mesothelial phenotype was determined by immunohistochemistry.
AQP1 function was inhibited by a pharmacological blocker (AqB050) or AQP1-specific siRNA. Cell proliferation, migration,
and anchorage-independent cell growth were assessed. A nude mouse heterotopic xenograft model of MM was utilised for the
in vivo studies. Results. Inhibition of AQP1 significantly decreases cell proliferation, metastatic potential, and motility without
inducing nonspecific cytotoxicity or increasing apoptosis. In vivo blockade of AQP1 had no biologically significant effect on growth
of established tumours. Conclusions. Targeted blockade of AQP1 restricts MM growth and migration in vitro. Further work is
warranted to fully evaluate treatment potential in vivo.
1. Introduction
Malignant mesothelioma (MM) is an aggressive tumour of
the serosal membranes. It most commonly affects the pleura
and is related to past inhalation of asbestos. The minimum
latency interval between the first exposure to asbestos and the
discovery of the MM is in excess 10 years. Once considered
a rare tumour [1], its incidence is projected to increase
in most industrialised countries in 2015–2020 [2, 3]. Many
recent cases are related to nonoccupational exposures (e.g.,
“handyman” exposures as a consequence of home renovation
work) and, due to this type of exposure, increasingly younger
patients are affected, some of whom sustained bystander
exposures as childrenwhen their parents renovated. Based on
conservative estimates of incidence, future economic liabili-
ties are estimated to reach around $200 billion in the US, $80
billion in Europe, and AU$8 billion in Australia [4–6].
MM has an extremely poor prognosis, because available
treatment strategies are limited. Radical surgery and combi-
nations of radiotherapy, immunotherapy, and chemotherapy
regimens are being trialed, but their benefits in terms of
patient survival are unproven at this stage [7, 8]. In light of the
limitations of current treatment strategies, new approaches
and novel targets are needed urgently.
Aquaporins (AQPs), a family of at least 13 transmembrane
water channel proteins, represent a potential target for cancer
therapy [9]. They have roles in the normal cellular processes
of water transport, proliferation, and pain perception [10–12]
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whereas, in cancer, AQP expression has been demonstrated to
play a role in the growth and metastatic potential of a variety
of tumours, including lung adenocarcinomas [9, 13–17].
AQP1 has also been demonstrated in the mesothelium
of the pleura and peritoneum [18, 19], and a role of AQP1
for pleural water transport across mesothelial cells has been
shown in a knockout mouse model [20]. We have previously
demonstrated AQP1 by electron microscopy at the apical
aspect of mesothelial cells, in keeping with that role in water
transport [21].
AQP1 can be expressed by vascular endothelium as well
as tumor cells, and blockade of AQP1 expressed by either
cell types in the tumour may be beneficial. The direct effects
of tumour-derived AQP1 expression on tumour growth
have been demonstrated in other models: melanoma cells
transfected with AQP1 showed increased growth and, in an
in vivomodel of melanoma, AQP1 blockade or inoculation of
melanoma into AQP1-deficient mice slowed tumour growth
by limiting vascular supply [22, 23]. It has been suggested
that modulation of tumour cells, either by specific AQP
inhibitors/blockers and agonists or by indirect modulation of
closely associated growth factors, may become a future treat-
ment strategy for some tumours [24, 25]. However, there was
insufficient knowledge about the functions of AQP1 in MM.
We have reported previously that AQP1 expression by
MM tumour cells is an independent prognostic factor for
improved survival times in malignant mesothelioma: higher
levels of AQP1 expression by tumour cells only (i.e., not vas-
cular cells) predict improved survival [21].We postulated that
higher AQP1 expression in these tumours may reflect better
differentiation, since normal mesothelium expresses AQP1.
We hypothesised that the retained expression of AQP1 in this
tumour may offer treatment potential to AQP1-expressing
tumours. MM characteristically grows by direct spread along
the pleural surface, where it forms nodules on the pleural
surface. This is thought to relate to the sliding motion of
tumour cells. AQP1 facilitates movement of both endothelial
cells and some tumour cells [23, 26–29]. Inhibition of this
type of cell motility/tumour growth especially may improve
patient survival.
We therefore investigated the role of AQP1 on MM cell
growth and movement and the effects of AQP1 blockade on
MM cells in vitro and in vivo using a heterotopic nude mouse
model.
2. Methods
2.1. Harvesting of Primary MM Cells from Pleural Effusions.
Cells from 15 separate pleural effusion fluids from 13 patients
(12 male and one female), aged between 65–94 years diag-
nosed with MM, were harvested. Two male subjects each
contributed two effusions to the study. The tumours were
diagnosed as epithelioid (12) and biphasic (3) subtypes. The
workwas approved by the SouthernAdelaideClinicalHuman
Research Ethics Committee (approval number 381.09).
2.2. Cell Culture. Pleural effusion specimens were cen-
trifuged at 500×g for 10min at 25∘C. The entire cell pellet
was placed into culture with complete DMEM (10% fetal
calf serum, 50U/mL penicillin, and 50 𝜇g/mL streptomycin;
Life Technologies, NY) and incubated at 37∘C with 5% CO
2
.
Culturemediumwas changed regularly, and the primary cells
were assessed by a panel of immunohistochemical markers
(Cam5.2, CK5/6, calretinin, D2-40 HBME-1,WT1, and nega-
tive markers BG8, TTF1, CD15, and BerEP4) to confirm their
mesothelial phenotype.The commercially available H226 cell
line (ATCC, Manassas, VA) was directly obtained from the
ATCC and cultured in complete DMEM for less than six
months. In addition, we confirmed mesothelial phenotype
by 2-month immunohistochemical analysis and electron
microscopy at the start of the experiments demonstrating
complex branchingmicrovilli. Pleural effusionMMcells were
only used in subsequent experiments if they were determined
to have >80% purity as assessed by immunohistochemistry
(see below).
2.3. Immunohistochemical Analysis. Cells harvested from
pleural effusions were resuspended in 1–3 drops of sheep
plasma. A drop of thrombin (0.5mL thrombin plus 9.5mL
0.1M CaCl
2
) was added to make a solid pellet, which
was fixed with 10% formalin, processed with graded con-
centrations of ethanol and isopropanol, and then embed-
ded in paraffin. Sections were cut 4 𝜇m thick, deparaf-





AQP1 immunohistochemistry was performed as previously
described [21]. Calretinin and CAM5.2 immunohistochem-
istry was performed with citric acid retrieval prior to the
addition of primary antibody (Calretinin; 1/5000; Invitrogen,
CAM5.2, 1/1000; BD Australia). Both methods utilized the
Novo Link polymer (LeicaMicrosystems,Wetzlar, Germany)
and DAB + Chromogen (Dako, CA, USA) detection systems
prior to hematoxylin counterstaining.
2.4. AQP1 Blocker. The AQP1 blocker (AqB050, US patent
7,906555B2) was purchased from Prof. Andrea Yool (Univer-
sity of Adelaide, Adelaide, SA 5000, SouthAustralia). Toxicity
was assessed using the ApoTox-Glo Triplex Assay (Promega
Madison WI) according to the manufacturer’s instruction to
assess viability, cytotoxicity, and apoptosis events, with no
toxicity identified at the tested concentrations.
2.5. siRNA Treatment. The H226 or primary MM cells were
plated at 2.5× 103 cells/well and 5× 103 cells/well, respectively,
in a 96-well plate before being reverse-transfected with
25 nM siRNA, as per manufacturer’s instructions (Silencer
Select siRNA,AppliedBiosystems, Life Technologies). Briefly,
siRNA (AQP1, GAPDH and siRNA Negative Control) was
complexed with 0.125 𝜇L Lipofectamine RNAimax in 50 𝜇L
of Opti MEM 1 reduced serum media for 10min before cell
dilutions were added (Life Technologies, NY). Medium was
changed after 24 h and cells cultured until vector controls
were confluent (4 days for H226 and 5 days for primary
cells) prior to being used in proliferation experiments. The
knockdown of genes by siRNA was confirmed with RT-PCR
and immunohistochemistry.
2.6. Quantitative RT-PCR. AQP1 and GAPDH knockdown
was confirmed by qRT-PCR. RNA extraction was performed
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using the RNeasy Mini Kit (QIAGEN); contaminating DNA
was removed using Turbo DNA-free (Ambion, Life Tech-
nologies) before cDNA synthesis using the Superscript III
First-Strand Synthesis system (Invitrogen, Life technologies,
NY) as per manufacturer’s instructions. AQP1 and GAPDH
qRT-PCR were performed using TaqMan Gene Expression
Assay system according to manufacturer’s protocol (Life
Technologies, NY). Peptidylprolyl isomerase A (PPIA) was
used as a housekeeping gene. AQP1 mRNA was routinely
knocked down to 6–17% of the vehicle control levels.
2.7. Cell Proliferation. Cell proliferation was assessed using
the CellTiter 96 AQueous Nonradioactive Cell Proliferation
Assay (MTS) kit (Promega Corporation, Madison, WI).
Briefly, H226 cells or primary cells were seeded in triplicate at
1.6 × 104 cells/well in a 96-well plate and were incubated for
24 h prior to cell proliferation test. For AQP1 blocker experi-
ments, cells were cultured for 23 h; then they were incubated
with control medium (DMEM alone or DMEM plus DMSO)
or medium containing the AQP1 inhibitor AqB050 for 1 h
prior to the cell proliferation test. The CellTiter 96 Aqueous
One Solution Reagent was added to each well and the plate
was incubated at 37∘C in a humidified, 5% CO
2
incubator for
2 h before the absorbance (490 nm) was measured.
2.8. Anchorage-Independent Assay. H226 cells (2 × 104 cells/
mL) were suspended in DMEM containing 20% FBS and 3%
agarose (Life Technologies, NY) with 20, 40, or 80 𝜇MAQP1
blocker or an equivalent volume of DMSO (vehicle control).
The cell suspension (2mL) was seeded into a 6-well plate on
top of a solid layer of 4mL DMEM containing 6% agarose
and 10% FBS. Each treatment was in duplicate and data is
from 3 separate experiments. Dishes were incubated for 3
weeks at 37∘C with 5% CO
2
, until colonies were visible to
the eye. Cells were stained with 0.2% crystal violet and were
counted using a brightfield microscope. To determine colony
size, 10 images were captured per well using AnalySIS getIT
software and F-view camera attached to an IX71 inverted
fluorescent scope with a 20x objective. Photos were analysed
using ImageJ software.
2.9. Scratch Assay. H226 cells were seeded overnight at 1.5
× 105 cells/well in a 24-well ImageLock microplate (Essen
Bioscience, Michigan, USA). A scratch was made through
the cell monolayer using a 4-pin WoundMaker (Essen Bio-
science). After a wash with RPMI medium, DMSO or the
AQP1 blocker was added in RPMI medium as indicated. Cell
migration was monitored by the Incucyte Kinetic Imaging
System (Essen Bioscience) every 2 h, up to 24 h after the
scratch. Representative cell scatter images were created by
tracking 10 evenly spaced cells (5 from each side of the
wound) on an 𝑥/𝑦 axis from the images taken over the first
12 h. ImageJ was used to measure 𝑥/𝑦 location between the
images and the points were plotted using Excel.
2.10. Animal Model. A subcutaneous xenograft model of
MM was used as described previously [30, 31]. H226 cells
were harvested, washed twice with PBS, and resuspended at
1 × 107 cells/mL in PBS. From this cell suspension, 100𝜇L
was injected subcutaneously with a 25G needle on a single
occasion in the hind flank of BALB/c nudemice. In the initial
dose-finding experiment, three groups of animals were exam-
ined: (1) mice treated with DMSO by daily intratumoural
injection (𝑛 = 5), (2) mice treated with AQP1 blocker at
20𝜇M by daily intratumoural injection (𝑛 = 6), and (3) mice
treated with AQP1 blocker at 80𝜇M by daily intratumoural
injection (𝑛 = 6). Injections were performed daily for
5 days, once tumours reached ∼50mm3. In the follow-up
experiment, three groups of animals were examined: (1)
untreated control mice (𝑛 = 6), (2) mice treated with AQP1
blocker at 20𝜇Mbydaily intratumoural injection (𝑛 = 5), and
(3) mice treated with DMSO by daily intratumoural injection
(𝑛 = 7). The AQP1 blocker was injected daily once the
tumours had reached∼100mm3. For this group, animals were
kept until tumour size reached 500mm3. All animals were
euthanised by CO
2
inhalation. Tumour width and length
were measured with calipers and used to calculate tumour
volume with the following formula: 𝑉 = length × width2 ×
0.52. Tumour growth was measured every 3 days. At the
conclusion of the experiments, the resulting xenografts were
excised, weighed, and processed for histological assessment.
The work was approved by Flinders University and Southern
Adelaide Local Health Network Animal Welfare Committee
(approval number 805/12).
2.11. Statistical Analysis. For the in vitro work, Pearson’s
correlation was used to analyse cell proliferation versusAQP1
expression. Curve estimation determined that the data fit a
quadratic model. Changes in proliferation and anchorage-
independent growth of MM following addition of AqB050
or siRNA were evaluated by ANOVA with Tukey’s post hoc
analysis or by an independent samples 𝑡-test. If data could
not be normalised it was analysed with the Friedman test
with Wilcoxon signed-rank post hoc analysis. The wound
healing assay and animal studies were analysed using a
repeated measures ANOVA with Tukey’s post hoc analysis.
All analyses were performed using SPSS forWindows version
17.0.
3. Results
3.1. Increased AQP1 Expression Is Associated with Cellular Pro-
liferation. PrimaryMM cells harvested from pleural effusion
fluids were cultured and proliferative activity was assessed by
MTS assay. Higher levels of AQP1 expression were associated
with higher rates of cell proliferation (𝑅2 = 0.485; 𝑃 = 0.026;
Figure 1).
3.2. Alteration of AQP1 Function and MM Cell Proliferation
In Vitro. To determine whether AQP1 plays a functional role
in MM cell proliferation, H226 cells and primary MM cells
were cultured in control media or in the presence of the
AQP1 blockerAqB050.TheH226 cell line shows expression of
AQP1 in >20% of tumour cells. There was a dose-dependent
decrease in proliferative activity when cells were incubated
with AqB050 for 1 h and, at 80𝜇M, there was a statistically
significant decrease in proliferative activity compared to the
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Figure 1: Higher AQP1 expression in primary MM cells correlates
with increased proliferation rates. Primary MM cells were seeded at
1.6 × 104 cells/well and were allowed to grow for 24 h. Cell prolifer-
ation was measured by MTS assay, 𝑛 = 14. Curve fit determined
a quadratic relationship. Analysed by Pearson’s correlation, 𝑅2 =
0.485; 𝑃 = 0.026.
Primary MM cell cultures where <20% of the cells
expressed AQP1 by IHC were designated as AQP1-low,
whereas in AQP1-high cultures ≥20% of the population
exhibited AQP1 expression. There was a statistically signif-
icant dose-dependent decrease in cell proliferation when
AQP1-high cells were treated with increasing doses of
AqB050 (𝑃 < 0.001; Figure 2(b)). However, the AQP1-low
cells showed no statistically significant difference in prolifera-
tion when exposed to AqB050 (𝑃 = 0.397; Figure 2(b)),
regardless of the concentration of the blocker used.
To exclude a nonspecific effect of AqB050 and to confirm
that the decrease in proliferation was in fact due to its
action on AQP1, we transfected H226 cells and primary MM
cells with AQP1 siRNA prior to measuring cell proliferation.
Like the pharmacological AQP1 blocker, the AQP1 siRNA
treatment significantly decreased cell proliferation rate in
both the H226 cells (𝑃 = 0.021) and the primary cells (𝑃 =
0.008, Figure 2(f)). The scrambled siRNA (H226, 𝑃 = 0.283;
primary, 𝑃 = 0.928) and GAPDH siRNA (H226, 𝑃 = 0.612;
primary, 𝑃 = 0.962) treatments did not result in decreased
cell proliferation. The specificity of the AQP1 siRNA treat-
ment was demonstrated by decreased expression of AQP1
mRNA (Figure 2(c)) and protein (Figures 2(d) and 2(e)).
3.3. Blockade of AQP1 Decreases Cell Motility and Anchorage-
Independent Growth. A scratch assay was used to determine
whether AQP1 blockade decreases MM cell motility. The
ability of MM cells to move to cover the scratch wound was
decreased in all AqB050-exposed MM groups in a dose-
dependent manner (Figure 3(a), 𝑃 ≤ 0.001). The position
of single cells was tracked by time-lapse photography over
12 h, and cells treated with 80 𝜇M AqB050 showed less
individual cell movement compared to cells in vehicle
control (Figures 3(b) and 3(c)). An anchorage-independent
growth assay, an indicator of metastatic growth potential,
was performed. When H226 cells were incubated with
increasing concentrations of AqB050, colony formation was
inhibited in all treatment groups compared to the vehicle
control (𝑃 = 0.001; Figure 4(a)). In addition to the smaller
number of colonies, the average colony size in the 80 𝜇M
treatment group was significantly smaller when compared to
the vehicle control (𝑃 = 0.039; Figure 4(b)).
3.4. Subcutaneous Xenograft Model of MM. A pilot study
using a BALBc/nude mouse subcutaneous xenograft model
ofMMwas used to assess the therapeutic potential of AqB050
in vivo and to determine a dose for future studies. Two doses
(20𝜇M and 80 𝜇M) were tested. There was no significant
effect of either treatments on tumour size after six days
(𝑃 = 0.334). However, tumours treated with 20𝜇M AqB050
appeared to have a different growth pattern, with tumours
appearing smaller than the vehicle-treated tumours at 3 days
(Figure 5(a)). To further assess this impression, a second pilot
study was conducted in the same animal model to see if this
effect was reproducible or if there might be a more significant
growth difference over a longer treatment period. However,
after 15 days of treatment, there was no significant effect of
treatment on tumour growth between treated, untreated, and
vehicle controls (𝑃 = 0.761; Figure 5(b)).
4. Discussion
AQP1 is expressed by normal mesothelium. Expression of
AQP1 is an independent prognostic factor in MM, with
high levels of AQP1 expression correlating with increased
survival in MM patients [21, 22]. Here we demonstrate for
the first time that increased AQP1 expression correlates with
increased cell proliferation in primary MM cells. This is in
line with published observations in malignant melanoma,
where increased AQP1 expression also correlated with faster
growth [23, 26]. We postulate that retained AQP1 expression
in MM indicates a more differentiated phenotype of the
tumour, with some retained expression of surface proteins,
which could be exploited for therapy. Therefore, because
expression of AQP1 can be easily assessed in biopsy samples,
this represents an attractive potential treatment for at least
a subset of MM patients, as therapy could be specifically
tailored depending on AQP1 expression levels. However,
whilst in vitro work was promising, in vivo pharmacological
blockade of AQP1 did not have a significant effect.
Exposure of MM of both cell lines and primary MM cells
with a pharmacological AQP1 blocker, AqB050, resulted in
significant decrease in MM cell proliferation at a concen-
tration well outside the toxic range. The specificity of the
effect being due to AQP1 blockade was confirmed by trans-
fecting both H226 cells and primary cells with AQP1 siRNA,
which resulted in comparable decrease of cell proliferation
compared to the controls. Further evidence supporting the
specificity of the effect being due to AQP1 blockade was
provided by the proliferation rates of those primaryMM cells
expressing low levels of AQP1 not being affected by the AQP1
blocker.These results are similar to those found in lung cancer
cells, where AQP1 overexpression was also associated with
increased proliferation [15].
We also demonstrated that AQP1 blockade in vitro
decreased cell movement in MM, as assessed in a wound-
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Figure 2:DecreasedAQP1 function reduces the rate of cell proliferation. (a)H226 cells treatedwithAqB050 showdose-dependent decrease in
proliferation, 𝑛 = 3. Error bars: SD. Analysed byANOVA,𝑃 = 0.021, with Tukey’s post hoc analysis,𝑃 = 0.016 (as indicated by∗). (b) Primary
cells treated with AqB050 show dose-dependent decrease in proliferation only in those populations where ≥20% of the MM population
expressedAQP1 (designated “high”); high 𝑛 = 8 and low 𝑛 = 3. Error bars: SEM, analysis by one-wayANOVA (high𝑃 < 0.001; low𝑃 = 0.397).
(c) AQP1 siRNA treatment decreased AQP1 mRNA levels in primary MM cells and H226 cells. Decrease of AQP1 mRNA levels following
siRNA knockdown was confirmed by RT-PCR. AQP1 mRNA was routinely decreased to 6–17% of the vehicle control levels. Shown is a
representative example of primaryMMcells. (d) AQP1 protein expression as assessed by immunohistochemistry (brown labeling) is preserved
on the cell surface of primary MM cells treated with scrambled siRNA. (e) AQP1 protein expression as assessed by immunohistochemistry
(brown labeling) is decreased on the cell surface of the same primaryMMcells treatedwithAQP1 siRNA. (f) AQP1 siRNA treatment decreases
proliferation of H226 and primaryMM (H226: 𝑛 = 3, one-way ANOVA𝑃 = 0.002, vector versus AQP1 siRNA𝑃 = 0.021; primary cells: 𝑛 = 3,









































Figure 3: AQP1 blockade decreases cell motility of H226 cells in a wound-healing assay. (a) Migration of cells in a scratch assay is decreased
in H226 cells treated with AqB050. Vehicle, 𝑛 = 4; 20 𝜇MAqB050, 𝑛 = 4; 40 𝜇MAqV050, 𝑛 = 3; 80 𝜇MAqB050, 𝑛 = 3. Analysis by repeated
measures ANOVA 𝑃 = 0.001 with Tukey’s post hoc analysis (20𝜇M 𝑃 = 0.03, 40𝜇M 𝑃 = 0.01, and 80𝜇M 𝑃 = 0.001; significance indicated
by ∗); error bars: SD. The position of 10 individual cells was tracked over 12 h by time-lapse photography. (b) Vehicle control medium. (c)
80 𝜇MAqB050 treatment.
as equivalent vehicle control treatments. In addition, we have
tracked motility of individual cells over a 12-hour period,
showing that individual cell motility was decreased. These
findings support previous observations in other tumour
models, where the ability of melanoma and breast cancer
cells to migrate in a transwell assay and cover a wound in
a scratch assay was significantly improved by transfection
with an AQP1 expression construct [23]. Similarly, targeted
disruption of AQP1 expression decreased cell motility in a
malignant melanoma model [26]. We have shown here for
the first time that, as in melanoma and breast cancer, AQP1
also promotes cell migration inMM.The reduction of colony
number and size of MM when cultured in the presence of
an AQP1 blocker in an anchorage-independent assay further
supports our findings that AQP1 expression in MM con-
tributes to cell motility. In melanoma cells this contribution
to motility has been linked to expression of 𝛽-catenin, and a
proportion of MM do express 𝛽-catenin [29, 32].
The ability of melanoma cells to form colonies in an
anchorage-independent assay correlated with the ability of
the same cells to produce metastases in an in vivo murine
model [26]. For MM, pharmacological blockade of AQP
reduced growth parameters in vitro in a similar fashion as
was observed in melanoma with siRNA treatment but, unlike
the melanoma model, in vivo therapy did not result in a
significant alteration of tumour growth [26]. This could be
due to a number of factors. It may be that the subcutaneous
xenograft model does not model some of the aspects of the
Disease Markers 7






































Figure 4: AQP1 blockade inH226 cells results in reduced colony number and size in an anchorage independent assay. (a) Number of colonies:
𝑛 = 3, 𝑃 = 0.001. Analysed by one-way ANOVA followed by Tukey’s post hoc analysis (A, B, and C indicate significant subgroups, 𝑃 ≤ 0.05).
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(b)
Figure 5: AQP1 blockade results in no difference in tumour size in H226 tumours in a subcutaneous xenograft model of MM. (a) A pattern
towards an early decrease in tumour size was noted in the initial dose-finding experiment: DMSO, 𝑛 = 5; 20 𝜇M AqB050, 𝑛 = 6; 80𝜇M
AqB050, 𝑛 = 6, 𝑃 = 0.334. (b) A longer follow-up experiment using the dose with the highest potential for improved response confirmed
no significant difference in tumor growth: untreated, 𝑛 = 6; 20𝜇MAqB050, 𝑛 = 5; DMSO, 𝑛 = 7, 𝑃 = 0.761. Analysis by repeated measures
ANOVA; error bars = SEM.
growth of mesothelioma well, such as the “sliding” motion of
tumour cells, which is an important part of tumour growth
in the native pleural space environment but which may
not be modeled well subcutaneously and which is not a
significant factor in melanoma. Alternatively, it is possible
that the drug may have interacted with blood proteins,
limiting bioavailability. Other factors include the type of drug
administration (local instead of systemic), dose (a relatively
small dose was used), and frequency of therapy (animals
were injected daily). Also, the in vivo half-life of AqB050
has not been characterised, and it is possible that the local
drug concentration did not reach therapeutic levels for long
enough. Finally, AQP1 is also expressed on some blood
components and vascular endothelium, so some of the drug
8 Disease Markers
could have been bound here, preventing it from reaching
therapeutic concentrations at the tumour cell level.
We have demonstrated here for the first time that AQP1
has a functional role in MM proliferation, movement, and
anchorage-independent growth. We have also demonstrated
that it is possible to decrease growth and movement of MM
in vitro by specific blockade of AQP1 using a pharmacological
blocker, verifying that the effect was due to interference with
AQP1 by siRNA.Our in vitro results suggest that AQP1 block-
ade may be a useful strategy to limit MM tumour growth, but
further in vivowork is required to fully evaluate the potential
of AQP1 blockade to contribute to therapy in MM.
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